{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:00:43Z","timestamp":1785193243457,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["110-2314-B-418-005-MY3"],"award-info":[{"award-number":["110-2314-B-418-005-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-418-007-MY3"],"award-info":[{"award-number":["113-2314-B-418-007-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jfma.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:30:43Z","timestamp":1747179043000},"page":"911-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST)"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-1166","authenticated-orcid":false,"given":"Yen-Wen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-0534","authenticated-orcid":false,"given":"Chao-Hung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran-Der","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Lieh","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Shen","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-I","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kai","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-0368","authenticated-orcid":false,"given":"Chieh-Lin","family":"Jerry Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2098-5922","authenticated-orcid":false,"given":"Wen-Jone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2025.05.006_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18990-3","article-title":"A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan","volume":"12","author":"Hou","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jfma.2025.05.006_bib2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jfma.2025.05.006_bib3","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.3390\/ijms23116336","article-title":"Molecular mechanism of pathogenesis and treatment strategies for AL amyloidosis","volume":"23","author":"Ikura","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.2019002762","article-title":"Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis","volume":"135","author":"Basset","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib5","first-page":"120","article-title":"Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis","volume":"12","author":"Palladini","year":"2005","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"25","key":"10.1016\/j.jfma.2025.05.006_bib6","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","article-title":"Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis","volume":"32","author":"Weiss","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.jfma.2025.05.006_bib7","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jfma.2025.05.006_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"Al amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2025.05.006_bib10","first-page":"148","article-title":"Guidelines of the Taiwan society of Cardiology for the diagnosis and treatment of heart failure with preserved ejection fraction","volume":"40","author":"Li","year":"2024","journal-title":"Acta Cardiol Sin"},{"issue":"1","key":"10.1016\/j.jfma.2025.05.006_bib11","first-page":"67","article-title":"Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"24","key":"10.1016\/j.jfma.2025.05.006_bib12","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients","volume":"119","author":"Sch\u00f6nland","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jfma.2025.05.006_bib14","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1002\/ajh.25440","article-title":"Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis","volume":"94","author":"Sidiqi","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.jfma.2025.05.006_bib15","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.mayocp.2017.09.016","article-title":"Prevalence of monoclonal gammopathy in wild-type Transthyretin amyloidosis","volume":"92","author":"Geller","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.jfma.2025.05.006_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jfma.2025.05.006_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.jfma.2025.05.006_bib18","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20 % or greater discriminate presentation, response, and survival in AL amyloidosis","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jfma.2025.05.006_bib20","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jfma.2025.05.006_bib21","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/j.clml.2018.07.292","article-title":"Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p","volume":"18","author":"Wong","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib22","first-page":"511","article-title":"Expert consensus of the Taiwan society of Cardiology on the diagnosis and treatment of cardiac amyloidosis","volume":"39","author":"Wang","year":"2023","journal-title":"Acta Cardiol Sin"},{"issue":"11","key":"10.1016\/j.jfma.2025.05.006_bib23","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jfma.2025.05.006_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJMoa010641","article-title":"Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure","volume":"345","author":"Drazner","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.05.006_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchf.2013.07.009","article-title":"Characterization of a novel symptom of advanced heart failure: bendopnea","volume":"2","author":"Thibodeau","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"37","key":"10.1016\/j.jfma.2025.05.006_bib26","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jfma.2025.05.006_bib27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [11C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imag"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13139-020-00681-4","article-title":"Nuclear imaging for cardiac amyloidosis: bone scan, SPECT\/CT, and amyloid-targeting PET","volume":"55","author":"Paeng","year":"2021","journal-title":"Nucl Med Mol Imag"},{"issue":"7","key":"10.1016\/j.jfma.2025.05.006_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11886-021-01506-2","article-title":"Potential cardiac amyloid PET\/CT imaging targets for differentiating immunoglobulin light chain from Transthyretin amyloidosis","volume":"23","author":"Schindler","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"10.1016\/j.jfma.2025.05.006_bib30","first-page":"1064","article-title":"Independent prognostic utility of 11C-pittsburgh compound B PET in patients with light-chain cardiac amyloidosis","volume":"63","author":"Choi","year":"2022","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib31","first-page":"1919","article-title":"Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images","volume":"29","author":"Santarelli","year":"2022","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol."},{"issue":"24","key":"10.1016\/j.jfma.2025.05.006_bib32","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jfma.2025.05.006_bib33","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.jfma.2025.05.006_bib34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jfma.2025.05.006_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.jfma.2025.05.006_bib36","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jfma.2025.05.006_bib37","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2019.218859","article-title":"Predicting survival in light chain amyloidosis","volume":"104","author":"Palladini","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.18.01398","article-title":"Validation of Mayo clinic staging system for light chain amyloidosis with high-sensitivity troponin","volume":"37","author":"Kumar","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2025.05.006_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.898033","article-title":"Diagnostic and prognostic values of cardiopulmonary exercise testing in cardiac amyloidosis","volume":"9","author":"Banydeen","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib40","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/ehf2.14406","article-title":"Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"10","author":"Cantone","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jfma.2025.05.006_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1002253","article-title":"Localized light chain amyloidosis: a self-limited plasmacytic B-cell lymphoproliferative disorder","volume":"12","author":"Mart\u00ednez","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.jfma.2025.05.006_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-020-00355-6","article-title":"Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy","volume":"10","author":"Milani","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.jfma.2025.05.006_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-020-00354-7","article-title":"Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis","volume":"10","author":"Sarosiek","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41375-018-0258-y","article-title":"Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib45","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis","volume":"103","author":"Manwani","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jfma.2025.05.006_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-021-00510-7","article-title":"Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib","volume":"11","author":"Ravichandran","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.jfma.2025.05.006_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ajh.25746","article-title":"Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis","volume":"95","author":"Sidana","year":"2020","journal-title":"Am J Hematol"},{"issue":"36","key":"10.1016\/j.jfma.2025.05.006_bib48","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15","key":"10.1016\/j.jfma.2025.05.006_bib49","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jfma.2025.05.006_bib50","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.jfma.2025.05.006_bib51","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.jfma.2025.05.006_bib52","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival","volume":"52","author":"Tandon","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jfma.2025.05.006_bib53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s002770000186","article-title":"Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure","volume":"79","author":"Zenh\u00e4usern","year":"2000","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jfma.2025.05.006_bib54","first-page":"1","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000681","article-title":"Summary of the EHA-ISA working group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis","volume":"6","author":"Sanchorawala","year":"2022","journal-title":"HemaSphere"},{"issue":"10","key":"10.1016\/j.jfma.2025.05.006_bib56","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.24453","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation","volume":"91","author":"Hwa","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.jfma.2025.05.006_bib57","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbmt.2014.08.002","article-title":"Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis","volume":"20","author":"Dhakal","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jfma.2025.05.006_bib58","first-page":"149","article-title":"Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series","volume":"21","author":"Lee","year":"2014","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"15","key":"10.1016\/j.jfma.2025.05.006_bib59","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.jfma.2025.05.006_bib60","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"10.1016\/j.jfma.2025.05.006_bib61","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib62","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2025.05.006_bib63","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.006_bib64","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood-2021-152540","article-title":"Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European myeloma network","volume":"138","author":"Kastritis","year":"2021","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jfma.2025.05.006_bib65","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jfma.2025.05.006_bib66","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jfma.2025.05.006_bib67","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jfma.2025.05.006_bib68","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.jfma.2025.05.006_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (pts) with relapsed\/refractory primary systemic AL amyloidosis (RRAL)","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jfma.2025.05.006_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib71","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jfma.2025.05.006_bib72","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2025.05.006_bib73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jfma.2025.05.006_bib74","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1074\/jbc.M110.178376","article-title":"Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils","volume":"286","author":"Giorgetti","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.jfma.2025.05.006_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.jfma.2025.05.006_bib76","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2025.05.006_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.121.055953","article-title":"Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial","volume":"145","author":"Shen","year":"2022","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jfma.2025.05.006_bib78","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib79","first-page":"86","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis."},{"issue":"11","key":"10.1016\/j.jfma.2025.05.006_bib80","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/archinte.1992.00400230061010","article-title":"Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients","volume":"152","author":"Gertz","year":"1992","journal-title":"Arch Intern Med"},{"issue":"19","key":"10.1016\/j.jfma.2025.05.006_bib81","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jfma.2025.05.006_bib82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archneur.63.4.noc50340","article-title":"Pyridostigmine treatment trial in neurogenic orthostatic hypotension","volume":"63","author":"Singer","year":"2006","journal-title":"Arch Neurol"},{"issue":"5 Suppl","key":"10.1016\/j.jfma.2025.05.006_bib83","first-page":"III338","article-title":"Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey","volume":"84","author":"Hosenpud","year":"1991","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib84","first-page":"202","article-title":"Long term results of heart transplantation in patients with amyloid heart disease","volume":"85","author":"Dubrey","year":"2001","journal-title":"Heart Br Card Soc"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib85","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ajt.16324","article-title":"Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib86","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"},{"issue":"5","key":"10.1016\/j.jfma.2025.05.006_bib87","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant"},{"issue":"2","key":"10.1016\/j.jfma.2025.05.006_bib88","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.jfma.2025.05.006_bib89","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:45:03Z","timestamp":1785192303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625002177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0929664625002177"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.05.006","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST)","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved.","name":"copyright","label":"Copyright"}]}}